Keyword: Cigna

Cigna's new program that will cover Novartis' Zolgensma and Spark's Luxturna, both pricey gene therapies, at no cost to patients.

Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.

In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.

Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.

On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim.

Mylan is taking another hit tied to its EpiPen pricing controversy.

Harvard Pilgrim broke new ground in the pay-for-performance arena, striking a first-ever deal for Eli Lilly's diabetes med Trulicity and the latest outcomes-based arrangement on Novartis' Entresto.

Pharma may have pulled off only a few outcomes-based pricing deals with payers, but companies are likely to add more to that list soon--many more, if payers have their way.